Skip to main content
Innoviva, Inc. logo

Innoviva, Inc. — Investor Relations & Filings

Ticker · INVA ISIN · US45781M1018 LEI · 549300ACOX4QTBES6535 US Financial and insurance activities
Open in API
Filings indexed 1,226 across all filing types
Latest filing 2017-08-22 Director's Dealing
Country US United States of America
Listing US INVA

About Innoviva, Inc.

https://www.inva.com/

Innoviva, Inc. is a diversified holding company that manages a portfolio of royalty-generating assets and operates a commercial-stage biopharmaceutical platform. The company's core royalty business is centered on respiratory therapies, providing a stable cash flow. Through its subsidiary, Innoviva Specialty Therapeutics, it focuses on developing and commercializing innovative treatments for patients in critical care and with infectious diseases. Innoviva's strategy involves leveraging its financial assets to invest in healthcare opportunities with high unmet medical needs, aiming to advance differentiated therapies and build a diverse portfolio of healthcare assets.

Recent filings

Filing Released Lang Actions
FORM 4 -
Director's Dealing
2017-08-22 English
FORM 4 -
Director's Dealing
2017-08-22 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content details the entry into a material definitive agreement, specifically a Credit Agreement involving a $250 million senior secured term loan, the termination of a prior material agreement, and the creation of a direct financial obligation. It also includes summaries of the agreements and references attached exhibits. There are no financial statements or comprehensive financial data presented, nor is this an earnings release or annual/interim report. The document primarily announces financing activity and changes in the company's capital structure. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length and detail support a high confidence in this classification.
2017-08-21 English
PROPOSED SALE OF SECURITIES
Regulatory Filings Classification · 100% confidence The document is a Form 144 filing with the U.S. Securities and Exchange Commission, which is a notice of proposed sale of securities pursuant to Rule 144 under the Securities Act of 1933. It details the sale of securities by a former affiliate, including the number of shares, dates, and broker information. This type of filing is specifically related to insider or affiliate sales of securities and is not a financial report, earnings release, or management discussion. It is a regulatory filing notifying the SEC and the public of a proposed sale of securities by an insider or affiliate. Therefore, it fits best under the category of Regulatory Filings (RNS), as it does not match any other more specific financial report or announcement category.
2017-08-10 English
10-Q
Interim / Quarterly Report Q2 2017
2017-08-08 English
8-K
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated August 7, 2017, by Innoviva, Inc. It reports the completion of a convertible note offering, details of the indenture, and related financial obligations. The content focuses on financing activities, including the issuance of convertible senior notes, terms of the notes, and use of proceeds. There are no financial statements or comprehensive financial performance data typical of annual or interim reports. The document is not a report publication announcement but a current report on material financing events. Therefore, it fits the category of Capital/Financing Update (CAP).
2017-08-07 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.